---
cssClass:
- wide
tags:
  - ðŸ§ª
---

# `Title:` [[Fragment Based Drug Design]]
--- 

- What led me here: [[Cheminformatics]] [[Drug Discovery]]
- [[Schrodinger]]

Inlinks
```dataview 
list from [[#this.file.name]] and !outgoing([[# this.file.name]]) 
```

# Fragment-Based Drug Design and In Silico Design

Fragment-based drug design (FBDD) and in silico design are two complementary approaches used in the discovery and development of new drugs. Both methods aim to identify small molecules that can interact with a target protein to modulate its activity.

## Fragment-Based Drug Design

FBDD is a method that starts with small, simple chemical structures â€“ or fragments â€“ that bind to different parts of a target protein. These fragments are typically low molecular weight compounds (less than 300 Da) with a simple structure.

The binding of these fragments to the target protein is usually weak, but they serve as starting points for the design of more potent compounds. By using techniques such as NMR spectroscopy or X-ray crystallography, researchers can determine how the fragments bind to the protein and then modify them to improve their binding affinity and other properties.

## In Silico Design

In silico design, also known as computer-aided drug design (CADD), involves the use of computational methods to design and optimize potential drug molecules. These methods can include:

- **Molecular docking**, which predicts how a small molecule (ligand) binds to a protein (receptor).
- **Molecular dynamics simulations**, which simulate the motion of atoms and molecules to study the physical properties of the system.
- **Quantitative structure-activity relationship (QSAR) modeling**, which uses statistical methods to relate the chemical structure of compounds to their biological activity.

In silico design can be used in conjunction with FBDD. For example, once fragments have been identified that bind to a target protein, computational methods can be used to predict how modifications to these fragments might affect their binding affinity and other properties.

## References

- Erlanson, D. A., Fesik, S. W., Hubbard, R. E., Jahnke, W., & Jhoti, H. (2016). Twenty years on: the impact of fragments on drug discovery. *Nature Reviews Drug Discovery*, 15(9), 605â€“619.
- Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004). Docking and scoring in virtual screening for drug discovery: methods and applications. *Nature Reviews Drug Discovery*, 3(11), 935â€“949.


AlogP
PSA
HBA
RB
